Drug Development Pipeline
AZD5634 is a compound designed to block the function of the sodium (Na+) channel found in the lungs. These channels move sodium and water away from the airway surface. Blocking these channels may help maintain fluid within the airways to improve mucus clearance.
A phase 1b study to test the safety and effectiveness of AZD5643 in adults with CF is underway.
This program is sponsored by AstraZeneca. This program is being conducted within the Therapeutics Development Network (TDN).
Recent AZD5634 Studies
Closed to Enrollment
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More